Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2021.107707 http://scihub22266oqcxt.onion/10.1016/j.intimp.2021.107707 33962224!8059942!33962224     free     free     free       Int+Immunopharmacol 2021 ; 97 (?): 107707 Nephropedia Template TP {{tp|p=33962224|t=2021. Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review |pdf=|usr=}}{{33962224}} gab.com Text Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33962224 #FOAvip Since late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, better known as COVID-19) has rapidly spread worldwide. The primary pathophysiology by which COVID-19 leads to severe lung damage is cytokine releasing syndrome (CRS), which can cause death. Therefore, removing cytokines via therapeutic plasma exchange or hemoperfusion could be a therapeutic approach to treat CRS. However, hemoperfusion or therapeutic plasma exchange could alter the effectiveness of concomitant medications. Thus, concomitant medication doses might need to be adjusted to prevent their elimination via therapeutic plasma exchange or hemoperfusion, thus ensuring that these medications remain effective. This narrative review investigates the elimination status of current medications used to manage COVID-19 during hemoperfusion and therapeutic plasma exchange, with a focus on their pharmacokinetic profiles. Twit Text FOAVip Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33962224 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33962224 #FOAvip English Wikipedia <ref>{{Cite pmid|33962224}}</ref> Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review #MMPMID33962224 Shokouhi S; Barati S; Kazeminia N; Jamali F; Roshan B; Sahraei Z Int Immunopharmacol 2021[Aug]; 97 (?): 107707 PMID33962224show ga Since late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, better known as COVID-19) has rapidly spread worldwide. The primary pathophysiology by which COVID-19 leads to severe lung damage is cytokine releasing syndrome (CRS), which can cause death. Therefore, removing cytokines via therapeutic plasma exchange or hemoperfusion could be a therapeutic approach to treat CRS. However, hemoperfusion or therapeutic plasma exchange could alter the effectiveness of concomitant medications. Thus, concomitant medication doses might need to be adjusted to prevent their elimination via therapeutic plasma exchange or hemoperfusion, thus ensuring that these medications remain effective. This narrative review investigates the elimination status of current medications used to manage COVID-19 during hemoperfusion and therapeutic plasma exchange, with a focus on their pharmacokinetic profiles. |*Drug Elimination Routes[MESH] |*Hemoperfusion[MESH] |*Plasma Exchange[MESH] |COVID-19/*therapy[MESH] |Humans[MESH]Evaluating the elimination status of medications used for COVID-19 dur(epmc).pdf DeepDyve Pubget Overpricing